Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
Seagen Inc. (SGEN) Create: Alert

All | News | Filings
Date FiledTypeDescription
04/26/2018 BW Seattle Genetics Reports First Quarter 2018 Financial Results
04/05/2018 BW Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter Financial Results on April 26, 2018
03/13/2018 BW Seattle Genetics to Present at the Barclays Global Healthcare Conference 2018
02/06/2018 BW Seattle Genetics Reports Fourth Quarter and Year 2017 Financial Results
01/18/2018 BW Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2017 Financial Results on February 6, 2018
12/04/2017 BW Seattle Genetics to Webcast Investor and Analyst Event at American Society of Hematology Annual Meeting
10/26/2017 BW Seattle Genetics Reports Third Quarter 2017 Financial Results
07/27/2017 BW Seattle Genetics Reports Second Quarter 2017 Financial Results
07/06/2017 BW Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter Financial Results on July 27, 2017
06/26/2017 BW Takeda and Seattle Genetics Announce Positive Results from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma
04/27/2017 BW Seattle Genetics Reports First Quarter 2017 Financial Results
04/06/2017 BW Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter Financial Results on April 27, 2017
03/01/2017 BW Seattle Genetics to Present at Upcoming Investor Conferences
02/09/2017 BW Seattle Genetics Reports Fourth Quarter and Year 2016 Financial Results
08/19/2011 BW Seattle Genetics Announces FDA Accelerated Approval of ADCETRIS™ (Brentuximab Vedotin) for Two Indications
06/27/2011 BW Seattle Genetics Achieves Milestone Under Millennium Collaboration for European Medicines Agency Acceptance of Brentuximab Vedotin MAA
06/09/2011 BW Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of Second Antibody-Drug Conjugate (ADC) Under Existing Collaboration
06/06/2011 BW Seattle Genetics and Millennium Present Updated Brentuximab Vedotin (SGN-35) Data at ASCO Annual Meeting
06/06/2011 BW Seattle Genetics Presents SGN-75 Clinical Data at ASCO Annual Meeting
06/01/2011 BW Seattle Genetics to Present at Upcoming Investor Conferences
05/27/2011 BW Millennium and Seattle Genetics Announce Brentuximab Vedotin (SGN-35) Presentations at 16th Congress of the European Hematology Association
05/05/2011 BW Seattle Genetics Reports First Quarter 2011 Financial Results
05/02/2011 BW Seattle Genetics Announces FDA Accepts Brentuximab Vedotin BLAs for Filing and Grants Priority Review for Relapsed or Refractory Hodgkin Lymphoma and Systemic ALCL
04/27/2011 BW Seattle Genetics to Present at Upcoming Investor Conferences
04/26/2011 BW Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2011 Financial Results on May 5, 2011
04/19/2011 BW Genmab and Seattle Genetics Expand Antibody-Drug Conjugate Collaboration
04/18/2011 BW Seattle Genetics Appoints Vice President, Corporate Development and Announces Management Promotion
04/06/2011 BW Seattle Genetics Reports Brentuximab Vedotin (SGN-35) Data at EBMT Annual Meeting
04/05/2011 BW Seattle Genetics Highlights ADC Technology Research at AACR
03/30/2011 BW Seattle Genetics to Present at Upcoming Investor Conferences
03/15/2011 BW Seattle Genetics and Millennium Expand Antibody-Drug Conjugate Collaboration
03/03/2011 BW Seattle Genetics to Present at Upcoming Investor Conferences
03/01/2011 BW Seattle Genetics and Millennium Announce Initiation of a Phase I Clinical Trial of Brentuximab Vedotin in Combination with Chemotherapy for Front-line Systemic ALCL
02/28/2011 BW Seattle Genetics Submits BLA to FDA for Brentuximab Vedotin in Relapsed or Refractory Hodgkin Lymphoma and Systemic ALCL
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy